Abstract
What is known and objectiveSince WHO declared the pandemic of COVID‐19, vaccines have been developed to fight against this infectious disease. Coordination and participation of investigational drug services to facilitate a phase III COVID‐19 vaccination clinical trial are described and discussed, with novel interventions coordinating the dispensing processes in the trailer settings.CommentOnce the study has reached phase III, the large number of participants and fast enrolment would contribute to the vaccine development.What is new and ConclusionThe investigational drug service (IDS) performed responsibilities in clinical and trailer units, and minimized workflow disturbances to maximize validity during the dispensing process. The advantages of mobile units and trailers increase flexibility of participants, broaden service area and improve feasibility, especially in minority and underserved communities. The UCM IDS team performs responsibilities in both clinical and mobile unit settings, the IDS team is able to facilitate and expand the enrolment to the minority population in underserved communities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
